Fig. 7.
Fig. 7. eGFP-specific CTLs lyse autologous CD34+cells transduced with the LZRS/eGFP vector. / eGFP-specific effector cells were generated from animals Mm 250-97 (A,B) and Mm 256-97 (C,D) by stimulation of PBMCs with autologous B-LCLs expressing eGFP and then tested for their ability to lyse either autologous B-LCLs (A,C) or CD34+ cells (B,D). Control target cells consisted of untransduced B-LCLs or CD34+cells. eGFP-expressing B-LCLs were stable cell lines obtained by cell sorting (> 90% eGFP+). eGFP-expressing CD34+cells were generated by transduction with the LZRS/eGFP vector in the presence of IL-3, SCF, and flt3 ligand. Levels of GFP expression were 32% for Mm 250-97 (B) and 54% for Mm 256-97 (D).

eGFP-specific CTLs lyse autologous CD34+cells transduced with the LZRS/eGFP vector.

eGFP-specific effector cells were generated from animals Mm 250-97 (A,B) and Mm 256-97 (C,D) by stimulation of PBMCs with autologous B-LCLs expressing eGFP and then tested for their ability to lyse either autologous B-LCLs (A,C) or CD34+ cells (B,D). Control target cells consisted of untransduced B-LCLs or CD34+cells. eGFP-expressing B-LCLs were stable cell lines obtained by cell sorting (> 90% eGFP+). eGFP-expressing CD34+cells were generated by transduction with the LZRS/eGFP vector in the presence of IL-3, SCF, and flt3 ligand. Levels of GFP expression were 32% for Mm 250-97 (B) and 54% for Mm 256-97 (D).

Close Modal

or Create an Account

Close Modal
Close Modal